Search Results
Your search for ,twO matches 11982 pages
Showing 551 - 600Salvage Reirradiation for Locally Recurrent Prostate Cancer: 7-Year Follow-up
In an update of a Norwegian trial reported in the Journal of Clinical Oncology, Ekanger et al found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good outcomes. Study Details The study included 38 patients with locally recurrent disease ...
Mortality Trends Among Asian American, Native Hawaiian, and Other Pacific Islander Patients With Preventable Cancers
The American Cancer Society (ACS) has detailed disparities in the mortality rates for preventable cancer types among Asian American, Native Hawaiian, and other Pacific Islander patients in a new Cancer Facts & Figures report published by Wagle et al. Background In this report, the Asian...
Breast Implant–Related Cancers: Should Our Patients Be Concerned?
The U.S. Food and Drug Administration (FDA) issued a safety communication,1 which was updated2 on March 22, 2023, informing the public that there have been reports of squamous cell carcinomas (SCC) and various lymphomas of the breast in the capsule or scar of breast implants. These lymphomas are ...
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma. Trastuzumab-strf is indicated for adjuvant treatment of...
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for...
Rapid Guideline Update Supports Capivasertib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update.1 The update was designed to orient clinicians to outcomes from the CAPItello-291 trial, which led to the U.S. Food...
Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers
The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excitement as they demonstrate high response rates in a population with unmet clinical needs, according...
Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?
Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective pilot study from Memorial Sloan Kettering Cancer Center. The investigators evaluated the use of...
AI Analysis of Cell-Free DNA Fragments and Protein Biomarkers for Noninvasive Detection of Ovarian Cancer
A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high specificity of more than 99%, according to study results by Medina et al.1 It noninvasively recognized ...
Breast Cancer Stalked My Family for Generations and Finally Came for Me
My maternal grandmother, mother, and two of my mother’s sisters were all diagnosed with breast cancer when they were relatively young, so I figured one day, the disease would come for me. Breast cancer is the most common cancer diagnosed among Alaska Native women,1 and at a very early age, my...
AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer
Researchers have developed a novel artificial intelligence (AI) model that may accurately predict whether patients with cancer will respond to certain therapies, according to a recent study published by Sinha et al in Nature Cancer. The findings indicated that single-cell RNA sequencing data may be ...
Zanubrutinib in Relapsed or Refractory Follicular Lymphoma
On March 7, 2024, the Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa) was granted accelerated approval in combination with the monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy...
Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer
In a UK-based prospective cohort study reported in The Lancet Oncology, Turtle et al found that among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those without a cancer diagnosis. Study Details The study included...
Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer
As reported in The Lancet Oncology by Ana Oaknin, MD, of the Medical Oncology Service at Vall d´Hebron Institute of Oncology, Vall d´Hebron Barcelona Hospital, and colleagues, the phase I/II CheckMate 358 trial showed that both nivolumab monotherapy and nivolumab/ipilimumab regimens were active...
Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors
Following a healthy diet may reduce the risk of cardiovascular disease in female breast cancer survivors, according to a recent study published by Ergas et al in JNCI Cancer Spectrum. Background Cardiovascular disease is one of the leading causes of non–breast cancer–related mortality among...
Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers
A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium. Results of the phase I/II trial showed an overall response rate of 13% and a...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with atezolizumab plus cabozantinib vs docetaxel after checkpoint inhibitor treatment and chemotherapy in patients with...
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...
Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone
As reported in The New England Journal of Medicine by de Boniface et al, the phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer and sentinel node metastases. Study Details In ...
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...
Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer
Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new cases of the cancer, and about 13,270 deaths from the disease. Ovarian cancer is largely...
Investigational Personalized Vaccine in Resected Head and Neck Cancers
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association...
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer
SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma
On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...
Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype
The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...
Fewer Than Half of Drugs Granted Accelerated Approval Demonstrated Benefit Within 5 Years
In 1992, the U.S. Food and Drug Administration (FDA) instituted its Accelerated Approval regulations, which allow drugs that treat serious conditions and fill an unmet need to be approved early based on a surrogate endpoint. However, any drug approved under this pathway is still required to undergo ...
Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma
Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...
Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced...
Microwave Ablation vs Surgical Resection in Multifocal Papillary Thyroid Carcinoma
Microwave ablation may offer comparable progression-free survival rates and fewer complications in patients with papillary thyroid carcinoma compared with surgical resection, according to a recent study published by Zhao et al in Radiology. Background Papillary thyroid carcinoma—the most common...
T-Cell Therapy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma
In a phase II trial (SPEARHEAD-1) reported in The Lancet, D’Angelo et al found that the T-cell therapy afamitresgene autoleucel showed activity in patients with previously treated HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma. As related by the...
Tuberculosis May Be Linked to Increased Risk of Various Cancer Types
The risk of certain types of cancer may be higher in patients currently or previously diagnosed with tuberculosis, according to new findings to be presented by Kim et al at the upcoming 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual congress. Background...
Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine...
T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC
As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer (NSCLC) cohorts of the phase II DESTINY-Lung01 trial show activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in this setting. Prior ...
Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer
Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...
Older Patients With AML: Does Stem Cell Transplant Improve Long-Term Outcomes?
Nearly 21,000 new cases of acute myeloid leukemia (AML) are diagnosed each year in the United States, about 80% of which occur in individuals aged 60 years and older. The cancer has the highest mortality rate among the different types of leukemia, and, in 2024, it is predicted that about 11,220...
Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...
Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...
Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes
Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...
FDA Approves Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic ...
Low-Dose Radiotherapy Boost in Young Patients With Breast Cancer
Researchers have found that a low-dose radiotherapy boost in addition to whole-breast radiotherapy may prevent local recurrence in young patients with breast cancer, according to new findings presented by Bosma et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 4LBA) and...
Erdafitinib for Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, 2024, erdafitinib (Balversa) was approved for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by a U.S. Food & Drug Administration–approved companion diagnostic test, whose disease has progressed on or...
In Resectable Non–Small Cell Lung Cancer, Perioperative Use of Tislelizumab Alone or With Chemotherapy Improved Outcomes
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment involving the checkpoint inhibitor tislelizumab led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the phase III RATIONALE-315 trial...
Is Hypofractionated Radiotherapy Emerging as the New Standard of Care After Prostatectomy?
It is currently acknowledged that hypofractionated radiotherapy, an increasingly favored approach in prostate cancer treatment, delivers higher radiation doses over fewer sessions compared with conventional fractionation schedules. This approach is supported by the recognition that prostate cancer ...
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...
